Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PTGX
#1031
Protagonist Therapeutics, Inc
92.080
0
+6.88%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+6.88%
Mudança mensal
+11.68%
Mudança em 6 meses
+22.56%
Mudança anual
+22.56%
Fechamento anterior
86.150
0
Open
92.210
0
Bid
Ask
Low
92.080
0
High
92.220
0
Volume
152
Mercados
Ações
Cuidados de saúde
PTGX
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
43.81 M
48.41 M
51.28 M
58.27 M
61.38 M
63.81 M
—
Valuation ratios
Enterprise value
765.82 M
1.53 B
427 M
1.18 B
2.27 B
5.44 B
15.61 B
Price to earnings ratio
—
—
-4.15
-16.85
9.13
-42.6
197.31
Price to sales ratio
—
—
19.89
22.16
5.78
120.66
173.34
Price to cash flow ratio
—
—
4.89
18.93
13.64
96.28
256.13
Price to book ratio
—
—
2.45
3.95
3.72
9.03
13.23
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.36
0.51
0.22
0.37
0.19
0.19
Return on equity %
0.24
0.42
0.59
0.23
0.41
0.21
0.2
Return on invested capital %
881.2
2 568.99
5 504.26
6 840.28
655.36
311.93
459.71
Gross margin %
100
100
100
100
100
100
400
Operating margin %
72.17 K
460.01
494.24
156.09
58.2
343.63
2 488.48
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
73.99 K
458.94
479.26
131.59
63.34
282.83
2 099.78
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
7.84
7.74
7.8
16.71
12.48
12.71
59.98
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.08
0.09
0.2
0.79
0.07
0.06
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.03
—
—
—
—
—
—
Long term debt to total equity ratio
0.04
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.2
1.24
2.83
0.91
0.93
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
4.84
6.02
6.44
8.92
36.06
Net current asset value per share
—
—
4.96
6.26
9.09
9.09
37.39
Tangible book value per share
—
—
4.4
5.93
10.38
9.67
41.25
Working capital per share
—
—
4.32
5.89
8.36
8.37
34.85
Book value per share
—
—
4.4
5.93
10.38
9.67
41.25
Notícias
Protagonist Therapeutics earnings missed by $0.35, revenue fell short of estimates
Citizens eleva preço-alvo de Protagonist Therapeutics após aprovações de medicamentos
Citizens raises Protagonist Therapeutics stock price target on drug approvals
Diretor da Protagonist Therapeutics vende US$ 1,48 milhão em ações
Protagonist Therapeutics director Williams sells $1.48 million in shares
Diretor da Protagonist Therapeutics vende ações no valor de US$ 1,67 milhões
Protagonist Therapeutics director sells $1.67 million in shares
Principais ações de biotecnologia para observar em 2026, segundo a Truist
Top Biotech Stocks to Watch in 2026, According to Truist
Preço-alvo das ações da Protagonist Therapeutics elevado para US$ 117 pela H.C. Wainwright
Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright
Protagonist Stock: Assessing The 2026 Upside For Icotrokinra And Rusfertide (PTGX)